A Comparison of Epidural Analgesia: Continuous Infusion Versus Programmed Intermittent Boluses

NCT ID: NCT02510287

Last Updated: 2016-05-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

128 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-31

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The analgesic approach in labor can be done in different ways, among which the neuraxial approach has shown the best analgesic results and fetal outcomes. Currently, programmed epidural intermittent bolus has been included in the neuraxial approach for a better distribution of the solution into the epidural space as compared with the continuous infusion strategy. In this study, the investigators seek to compare both strategies in 132 laboring women.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Labor Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Continuous Epidural Infusion

1. An initial dose of 10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution) will be given.
2. A continuous infusion of 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour) will then be administered.
3. Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.
4. If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered.

Group Type ACTIVE_COMPARATOR

Bupivacaine and Fentanyl Initial Dose

Intervention Type DRUG

10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution)

Bupivacaine and Fentanyl: Continuous Epidural Infusion

Intervention Type DRUG

0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour)

Rescue Bolus

Intervention Type DRUG

Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.

Lidocaine

Intervention Type DRUG

If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered.

Programmed Intermittent Epidural Bolus

1. An initial dose of 10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution) will be given.
2. A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour.
3. Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.
4. If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered .

Group Type EXPERIMENTAL

Bupivacaine and Fentanyl Initial Dose

Intervention Type DRUG

10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution)

Bupivacaine and Fentanyl: Programmed Intermittent Epidural Bolus

Intervention Type DRUG

A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour

Rescue Bolus

Intervention Type DRUG

Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.

Lidocaine

Intervention Type DRUG

If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bupivacaine and Fentanyl Initial Dose

10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution)

Intervention Type DRUG

Bupivacaine and Fentanyl: Continuous Epidural Infusion

0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour)

Intervention Type DRUG

Bupivacaine and Fentanyl: Programmed Intermittent Epidural Bolus

A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour

Intervention Type DRUG

Rescue Bolus

Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.

Intervention Type DRUG

Lidocaine

If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At term pregnancy
* Laboring patients requiring epidural analgesia

Exclusion Criteria

* American Society of Anesthesiologists physical status \> or equal than 3
* allergy to local anesthesics
* Neuraxial contraindications
* Hemodynamic instability
* Systemic disease such as diabetes mellitus or hypertension
* Chronic usage of analgesics
* Disease associated to pregnancy such as gestational diabetes, preeclampsia, fetal malformations among others
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fundación Santa Fe de Bogota

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Leopoldo Ferrer

MD anesthesiologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Universitario Fundación Santa Fe

Bogotá, Bogota D.C., Colombia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Colombia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CCEI-3413-2015

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.